CRISPR/Cas9 genome engineering in hematopoietic cells
- The development of genome editing tools capable of modifying specific genomic sequences with unprecedented accuracy has opened up a wide range of new possibilities in targeted gene manipulation. In particular, the CRISPR/Cas9 system, a repurposed prokaryotic adaptive immune system, has been widely adopted because of its unmatched simplicity and flexibility. In this review we discuss achievements and current limitations of CRISPR/Cas9 genome editing in hematopoietic cells with special emphasis on its potential use in ex vivo gene therapy of monogenic blood disorders, HIV and cancer.
Download full text files
Additional Services
| Author: | Duran Sürün, Harald von Melchner, Frank SchnütgenORCiDGND |
|---|---|
| URN: | urn:nbn:de:hebis:30:3-514012 |
| DOI: | https://doi.org/10.1016/j.ddtec.2018.08.001 |
| ISSN: | 1740-6749 |
| Pubmed Id: | https://pubmed.ncbi.nlm.nih.gov/30205879 |
| Parent Title (English): | Drug discovery today. Technologies |
| Publisher: | Elsevier |
| Place of publication: | Amsterdam [u.a.] |
| Contributor(s): | Milena Bellin |
| Document Type: | Article |
| Language: | English |
| Year of Completion: | 2018 |
| Date of first Publication: | 2018/08/25 |
| Publishing Institution: | Universitätsbibliothek Johann Christian Senckenberg |
| Release Date: | 2019/10/21 |
| Volume: | 28 |
| Page Number: | 7 |
| First Page: | 33 |
| Last Page: | 39 |
| Note: | © 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| HeBIS-PPN: | 455688702 |
| Institutes: | Medizin / Medizin |
| Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
| Sammlungen: | Universitätspublikationen |
| Licence (German): |  Creative Commons - Namensnennung 4.0 |
